HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Zzzquil Efficacy Tests, P&G Highlights OTC Sleep Aid Indication

This article was originally published in The Tan Sheet & The Rose Sheet

Executive Summary

Sleep researchers recognize many consumers look at Rx sleep disturbance treatments and OTC sleep aids as the same type of products. Still, "people are looking for options that are effective and non-habit-forming and help them get to sleep quickly," says P&G researcher Andrew Carr.

You may also be interested in...



P&G Launches ZzzQuil To Enter OTC Sleep Aid Category

While other national brand names compete in the OTC sleep aid tablet category, P&G’s NyQuil line extension is by far the biggest name among current players in the liquid product category, which has annual growth of nearly 80%.

Pataday Switch Appoval Dilates Eye Drop Category As Alcon's OTC Sales Driver

With Pataday Once Daily Relief (0.2% olopatadine) and Twice Daily (0.1%), Alcon adds allergy treatment to its lineup of OTC drops indicated for dry eye and redness. “Obviously, eye allergy will become a much bigger part of the portfolio for us,” says US vision care GM Sean Clark.

GSK Leaving Pennsylvania Emergen-C Plant, Adding Voltaren To US OTC Line

UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed making the Emergen-C line. It will move the manufacturing to its Guayama, PR, facility.

Topics

Related Companies

UsernamePublicRestriction

Register

RS122990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel